These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23322007)

  • 1. Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.
    Kochhar S
    Hum Vaccin Immunother; 2013 Apr; 9(4):928-31. PubMed ID: 23322007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinology capacity building in Europe for innovative platforms serving emerging markets.
    Hendriks J; Holleman M; Hamidi A; Beurret M; Boog C
    Hum Vaccin Immunother; 2013 Apr; 9(4):932-6. PubMed ID: 23563518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partnering for Vaccine Emerging Markets--Berlin, June 10-11, 2013: balancing vaccine quality, capacity, and cost-of-goods in emerging markets.
    Onraedt A
    Hum Vaccin Immunother; 2013 Sep; 9(9):2022-4. PubMed ID: 23966097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics and financing of vaccines for diarrheal diseases.
    Bartsch SM; Lee BY
    Hum Vaccin Immunother; 2014; 10(6):1568-81. PubMed ID: 24755623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and impact of conducting vaccine trials in Asia and Africa: New Technologies in Emerging Markets, October 16th-18th 2012; World Vaccine Congress, Lyon.
    Kochhar S
    Hum Vaccin Immunother; 2013 Apr; 9(4):924-7. PubMed ID: 23321645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious disease research investments: systematic analysis of immunology and vaccine research funding in the UK.
    Fitchett JR; Head MG; Atun R
    Vaccine; 2013 Dec; 31(50):5930-3. PubMed ID: 24176489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines for epidemic infections and the role of CEPI.
    Plotkin SA
    Hum Vaccin Immunother; 2017 Dec; 13(12):2755-2762. PubMed ID: 28375764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality vaccines for all people: Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand.
    Pagliusi S; Ting CC; Khomvilai S;
    Vaccine; 2016 Jun; 34(31):3562-7. PubMed ID: 26947496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines: from valuation to resource allocation.
    Bloom DE; Madhavan G
    Vaccine; 2015 Jun; 33 Suppl 2():B52-4. PubMed ID: 26022569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complexity and cost of vaccine manufacturing - An overview.
    Plotkin S; Robinson JM; Cunningham G; Iqbal R; Larsen S
    Vaccine; 2017 Jul; 35(33):4064-4071. PubMed ID: 28647170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whither vaccines?
    Rodrigues CMC; Pinto MV; Sadarangani M; Plotkin SA
    J Infect; 2017 Jun; 74 Suppl 1():S2-S9. PubMed ID: 28646957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities for vaccine research in Europe.
    Gancberg D; Hoeveler A; Martini A; Draghia-Akli R
    Hum Vaccin Immunother; 2015; 11(8):1917-20. PubMed ID: 26090718
    [No Abstract]   [Full Text] [Related]  

  • 15. Roadmap for the establishment of a European vaccine R&D infrastructure.
    Leroy O; Geels M; Korejwo J; Dodet B; Imbault N; Jungbluth S
    Vaccine; 2014 Dec; 32(51):7021-7024. PubMed ID: 25148773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine development costs: a review.
    Waye A; Jacobs P; Schryvers AB
    Expert Rev Vaccines; 2013 Dec; 12(12):1495-501. PubMed ID: 24160863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desirable attributes of vaccines for deployment in low-resource settings.
    Chen D; Zehrung D
    J Pharm Sci; 2013 Jan; 102(1):29-33. PubMed ID: 23136115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine provision: Delivering sustained & widespread use.
    Preiss S; Garçon N; Cunningham AL; Strugnell R; Friedland LR
    Vaccine; 2016 Dec; 34(52):6665-6671. PubMed ID: 27884478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are good intentions putting the vaccination ecosystem at risk?
    Watson M; Faron de Goër E
    Hum Vaccin Immunother; 2016 Sep; 12(9):2469-74. PubMed ID: 27269046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.